Twist Bioscience Corp
TWST Nasdaq
SEC CIK 1581280
Follow Twist Bioscience
Weekly email: filings, results
Revenue, last quarter
$126.6M
+27.9% vs same quarter last year
Net income
−$20.6M
+24% vs same quarter last year
EPS, diluted
-
Operating cash flow
−$173K
+98.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY26 | $459.4M | −$130.2M |
| FY25 | $376.6M | −$77.7M |
| FY24 | $313M | −$208.7M |
| FY23 | $245.1M | −$204.6M |
| FY22 | $203.6M | −$217.9M |
| FY21 | $132.3M | −$152.1M |
| FY20 | $90.1M | −$139.9M |
| FY19 | $54.4M | −$107.7M |
| FY18 | $25.4M | −$71.2M |
| FY17 | $10.8M | −$59.3M |
| FY16 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY26 | 52.4% | −30.4% | −28.3% |
| FY25 | 50.7% | −36.2% | −20.6% |
| FY24 | 42.6% | −70.6% | −66.7% |
| FY23 | 36.6% | −88.6% | −83.5% |
| FY22 | 41.4% | −115.3% | −107% |
| FY21 | 39.1% | −115.4% | −114.9% |
| FY20 | 31.8% | −155.5% | −155.3% |
| FY19 | 12.8% | −200.1% | −198% |
| FY18 | −26.6% | −277.5% | −280.2% |
| FY17 | −123.1% | −543.2% | −550.8% |
| FY16 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY26 | −$89M |
| FY25 | −$75.6M |
| FY24 | −$69.2M |
| FY23 | −$170.3M |
| FY22 | −$226.2M |
| FY21 | −$139.3M |
| FY20 | −$152.1M |
| FY19 | −$102.7M |
| FY18 | −$69.9M |
| FY17 | −$57.9M |
| FY16 | - |
- Twist Bioscience
- Healthcare median
Show the numbers
| Year | Twist Bioscience | Healthcare median |
|---|---|---|
| FY26 | −28.3% | −11.1% |
| FY25 | −20.6% | −30.6% |
| FY24 | −66.7% | −47% |
| FY23 | −83.5% | −58% |
| FY22 | −107% | −80.4% |
| FY21 | −114.9% | −71.9% |
| FY20 | −155.3% | −62.2% |
| FY19 | −198% | −46.3% |
| FY18 | −280.2% | −49.6% |
| FY17 | −550.8% | −45.9% |
| FY16 | - | −36% |